<DOC>
	<DOCNO>NCT01787786</DOCNO>
	<brief_summary>The purpose study develop predictive model allow optimize dosing infliximab individual patient</brief_summary>
	<brief_title>Improving Treatment Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug Antibody Levels</brief_title>
	<detailed_description>The use pharmacokinetic analysis incorporate relevant determinant infliximab serum concentration use develop predictive model allow optimize dose individual patient .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>diagnosis CD UC usual criterion , moderate severely active CD define CDAI ≥ 220 , confirm endoscopic activity ( CDEIS ≥ 6 ) moderate severely active UC , define Mayo Score ≥ 6 , Mayo endoscopic subscore ≥ 2 , need treatment IFX induction remission clinically indicated patient previously expose adalimumab and/or certolizumab naïve infliximab allow participate . perianal CD exclusively disease limited rectum patient UC ( i.e. , disease must extend ≥ 15 cm anal verge ) patient know antibody IFX ( ADAs ) baseline contraindication infliximab therapy contraindication endoscopy ostomy plan surgery evidence severe unstable hepatic , gastrointestinal , cardiovascular , respiratory , neurological , psychiatric , hematological renal disease discretion investigator , Pregnancy breastfeeding , treatment investigational drug past 30 day , 5 half life ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Optimal Use infliximab</keyword>
</DOC>